Key Takeaways & Executive Findings
- •• The optimal extraction conditions for volatile oil from Fructus Alpiniae Oxyphyllae were determined using orthogonal design. • Extraction time, amount of water, and soaking time significantly affect the yield of volatile oil. • The maximum yield of volatile oil (1.2%) was achieved under the optimized conditions. • The study provides a scientific basis for the industrial production of volatile oil from this medicinal plant.
Abstract
The extraction process of volatile oil from Fructus Alpiniae Oxyphyllae was optimized by orthogonal design. The effects of extraction time, amount of water, and soaking time on the yield of volatile oil were investigated. The optimal conditions were determined as follows: extraction time of 6 hours, amount of water of 8 times the weight of the drug, and soaking time of 1 hour. Under these conditions, the yield of volatile oil was 1.2%. The results provide a reference for the industrial production of volatile oil from Fructus Alpiniae Oxyphyllae.
1. Introduction
Fructus Alpiniae Oxyphyllae, a traditional Chinese medicine, has been widely used for its various pharmacological activities. Volatile oil is one of the main active components, possessing anti-inflammatory, antioxidant, and neuroprotective effects. The extraction process of volatile oil is crucial for its quality and yield. Orthogonal design is a statistical method used to optimize multiple factors with fewer experiments. In this study, we aimed to optimize the extraction process of volatile oil from Fructus Alpiniae Oxyphyllae using orthogonal design, providing a reference for its industrial production.
Loading authentic research manuscript (Pages 1–5)...
Unknown (2026). Optimization of Extraction Process of Volatile Oil from Fructus Alpiniae Oxyphyllae by Orthogonal Design. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_18
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the optimal extraction time for volatile oil from Fructus Alpiniae Oxyphyllae?
The optimal extraction time was found to be 6 hours.
What is the optimal amount of water for extraction?
The optimal amount of water was 8 times the weight of the drug.
What is the optimal soaking time?
The optimal soaking time was 1 hour.
What is the maximum yield of volatile oil achieved?
The maximum yield of volatile oil was 1.2% under the optimized conditions.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.